"The U.S. Food and Drug Administration today approved the first generic version of Copaxone (glatiramer acetate injection), used to treat patients with relapsing forms of multiple sclerosis (MS).
Sandoz has received FDA approval to market "...
There is no experience regarding teriflunomide overdose or intoxication in humans. Teriflunomide 70 mg daily up to 14 days was well tolerated by healthy subjects.
AUBAGIO is contraindicated in/with:
- Patients with severe hepatic impairment [see WARNINGS AND PRECAUTIONS].
- Pregnant women or women of childbearing potential not using reliable contraception. AUBAGIO may cause fetal harm [see WARNINGS AND PRECAUTIONS and Use In Specific Populations].
- Patients with a history of a hypersensitivity reaction to teriflunomide, leflunomide, or to any of the inactive ingredients in AUBAGIO. Reactions have included anaphylaxis, angioedema, and serious skin reactions [see WARNINGS AND PRECAUTIONS].
- Co-administration with leflunomide [see CLINICAL PHARMACOLOGY].
Last reviewed on RxList: 6/16/2016
Additional Aubagio Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.